2021-09-06
표적단백질분해(targeted protein degradation, TPD) 신약개발 바이오텍인 아이비스바이오(Aevis Bio)가 시리즈A로 100억원의 투자유치를 마무리했다고 6일 밝혔다. 이번 라운드에는 KB인베스트먼트, 위벤처스, 타임폴리오자산운용 등이 참여했다.
NEWS PROVIDED BY
2021-07-31
Researches on immunomodulatory imides drug development under the Cooperative Research and Development Agreement (CRADA) with the National Institutes of Health (NIH) have been published in the peer-reviewed publication, Int J Mol Sci. (July 31, 2021).
NEWS PROVIDED BY
2021-04-02
The therapeutic efficacy results of a candidate immunomodulatory imide drug developed under the Cooperative Research and Development Agreement (CRADA) with the National Institutes of Health (NIH) have been published in the peer-reviewed publication, ACS P
NEWS PROVIDED BY
2021-03-30
Research on the immunomodulatory imide drugs development under the Cooperative Research and Development Agreement (CRADA) with the National Institutes of Health (NIH) have been published in the peer-reviewed publication, Frontiers in Neuroscience (March 2
NEWS PROVIDED BY
2021-02-01
AevisBio opened Chemical Research Center at Institut Pasteur Korea (IPK) in Pan-gyo, Korea
NEWS PROVIDED BY
2021-01-15
AevisBio, Inc., a company specializing in developing therapeutics for anti-inflammatory diseases, has entered into a collaborative research with the National Cancer Institute, an institute of the National Institutes of Health (NIH), U.S. Department of Hea
NEWS PROVIDED BY
2021-01-11
Aevisbio and NIH signed the patent license agreement in relation to the development of thalidomide analogues for the treatment of neurological disorders. In accordance of CRADA, Aevisbio and NIH will collaborate to develop the thalidomide analogues in pre
NEWS PROVIDED BY
2021-01-01
Selected a new drug development program including government grant (₩6B) from National Research Foundation of Korea. This program will enable AevisBio to further develop the TPD platform technologies. AevisBio will open the Chemical Research Center at Ins
NEWS PROVIDED BY
2020-09-14
The therapeutic efficacy results of a candidate immunomodulatory imide drug developed under the Cooperative Research and Development Agreement (CRADA) with the National Institutes of Health (NIH) have been published in the peer-reviewed publication, eLife
NEWS PROVIDED BY Aevisbio, Inc.
2020-06-01
In June of 2020, AevisBio and Korea Research Institute of Standards and Science (KRISS) announced a collaboration to develop technologies for treating infectious disease especially focused on COVID19.
NEWS PROVIDED BY
2020-06-01
Awarded two post-TIPS grants (₩1B each) from Ministry of SMEs and Startups (Korean government).
NEWS PROVIDED BY
2019-10-07
13 Korean Tech Startups Pitch to prominent investors in the Nation's Capital…
NEWS PROVIDED BY Korea Innovation Center Washington DC
2019-10-04
AevisBio, Inc., a company specializing in developing therapeutics for anti-inflammatory diseases has entered into a cooperative research and development agreement with the National Institute on Aging (NIA), an institute of the National Institutes of Healt
NEWS PROVIDED BY
2019-08-01
Awarded TIPS (Accelerator Investment-Driven Tech Incubator Program for Startup) investment (₩5B) from Ministry of SMEs and Startups (Korean government) with matching fund ($150K) from Bluepoint Partners. The funding will enable AevisBio to further develop
NEWS PROVIDED BY
2019-07-01
In July of 2019, AevisBio and Korea Research Institute of Bioscience & Biotechnology (KRIBB) announced a collaboration to discover, develop, and commercialize therapies for treating disease of aging, including Parkinson’s disease.
NEWS PROVIDED BY
2019-06-01
AevisBio opened Bio Research Center at BVC, Korea Research Institute of Bioscience and Biotechnology (KRIBB) in Daejeon Korea
NEWS PROVIDED BY
2018-09-27
2018-09-27 Aevis Bio, Inc, founded in Daejeon, Korea. 2019-04-11 AevisBio, Inc. founded in Gaithersburg, MD USA
NEWS PROVIDED BY